Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B

Antiviral Therapy

Volumn 16, Issue 1, 2011, Pages 77-87

  Han, Kyung Ho ^a,b   Hong, Sun Pyo ^c   Choi, Seo Hee ^c   Shin, Soo Kyung ^c   Cho, Sung Won ^d   Ahn, Sang Hoon ^e   Hahn, Ji Sook ^b   Kim, Soo Ok ^c  

^a Korea Food and Drug Administration   (South Korea)

^b Seoul National University   (South Korea)

^c GeneMatrix Inc   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ARTICLE; CHRONIC HEPATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MASS SPECTROMETRY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEIC ACID ANALYSIS; PERFORMANCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT MASS POLYMORPHISM ASSAY; SEQUENCE ANALYSIS; SERUM; VIRUS IDENTIFICATION; VIRUS MUTATION;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MASS SPECTROMETRY; MUTATION; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 79951477782     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1702     Document Type: Article

References (31)

1. Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132:723-731. (Pubitemid 30244172)
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129. (Pubitemid 38298992)
3. Iloeje UH, Yang H, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
5. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532. (Pubitemid 32496991)
6. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117. (Pubitemid 36055344)
7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68. (Pubitemid 28304879)
8. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005; 352:2743-2746. (Pubitemid 41007830)
9. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25:9-19. (Pubitemid 41254589)
10. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
11. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
12. Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol 2006; 36:8-12. (Pubitemid 44382729)
13. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507. (Pubitemid 39129351)
14. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307-313. (Pubitemid 46374587)
15. Mukaide M, Tanaka Y, Shin-I T, et al. The mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. Antimicrob Agents Chemother 2010; 54:882-889.
16. Sheldon J, Rodes B, Zoulim F, et al. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006; 13:427-434.
17. Fung SK, Fontana RJ. Management of drugresistant chronic hepatitis B. Clin Liver Dis 2006; 10:275-302.
18. de Vries-Sluijs TE, van der Eijk AA, Hansen BE, et al. Wild type and YMDD variant of hepatitis B virus: no difference in viral kineitcs on lamivudine/tenofovir therapy in HIV-HBV coinfected patients. J Clin Virol 2006; 36:60-63. (Pubitemid 44360570)
19. Pas SD, de Man RA, Fries E, et al. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridization. J Clin Virol 2002; 25:63-71. (Pubitemid 34765764)
20. Paik YH, Han KH, Hong SP, et al. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther 2006; 11:447-455. (Pubitemid 44024852)
21. Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40:837-844. (Pubitemid 38507366)
22. Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10:441-449. (Pubitemid 41151022)
23. Hong SP, Shin SK, Lee EH, et al. High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry. Nat Protoc 2008; 3:1476-1484.
24. Oh HB, Kim SO, Cha CH, et al. Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5′ untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism. J Med Virol 2008; 80:1712-1719.
25. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391. (Pubitemid 43980117)
26. Kim YJ, Kim SO, Chung HJ, et al. Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. Clin Chem 2005; 51:1123-1131. (Pubitemid 43079388)
27. Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130:1144-1152.
28. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55:1488-1495. (Pubitemid 44476796)
29. Cheong JY, Cho SW, Yoo JH, et al. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B. Hepatogastroenterology 2008; 55:1029-1033.
30. Aberle SW, Kletzmayr J, Watschinger B, et al. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001; 39:1972-1974. (Pubitemid 32417056)
31. Ono Y, Onda H, Sasada R, et al. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983; 11:1747-1757.